Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced the completion of its acquisition of the Purification & Filtration business of Solventum (NYSE: SOLV) for approximately $4.0 billion in cash. With the transaction complete, the business, which is now Thermo Fisher’s Filtration and Separation business, is part of the Life Sciences Solutions segment.

According to public statistics, the transaction value of the global TOP10 healthcare M&A deals in 2021 will all be more than $3 billion, of which Thermo Fisher’s acquisition of PPD for $17.4 billion ranks first

The European Commission has opened an investigation assess whether Illumina's decision to complete its acquisition of Grail is a breach of the “standstill obligation”